Obesity Drug Pipeline Tracker
Live overview of obesity and metabolic drugs by clinical phase — from Phase 3 assets like CagriSema and retatrutide through to preclinical candidates.
Approved
- Wegovy / Ozempic (semaglutide) — Novo Nordisk
- Zepbound / Mounjaro (tirzepatide) — Eli Lilly
- Foundayo (orforglipron) — Eli Lilly
- Wegovy pill (oral semaglutide) — Novo Nordisk
Phase 3
- CagriSema (cagrilintide + sema) — Novo Nordisk
- Retatrutide (LY3437943) — Eli Lilly
- MariTide (AMG 133) — Amgen
- VK2735 (SC) (GLP-1/GIP) — Viking Therapeutics
- Petrelintide (ZP8396) — Zealand / Roche
- Zenagamtide (amycretin; GLP-1 + amylin) — Novo Nordisk
Phase 2
- VK2735 (oral) (GLP-1/GIP) — Viking Therapeutics
- Aleniglipron (GSBR-1290) — Structure Tx
- Pemvidutide (ALT-801) — Altimmune
- MET-233i — Pfizer / Metsera
Phase 1
- MET-097i (ultra-long GLP-1) — Metsera
- Next-gen amylin (early clinical) — Multiple
- Oral combinations (dose-finding) — Multiple
- ACCG-2671 — Structure Therapeutics
- VK3019 — Viking Therapeutics
- AMG 513 — Amgen
- AT-7687 — Antag Therapeutics
- CT-996 — Roche
- VRB-101 — Verdiva Bio
Preclinical
- Metabolic candidates (various) — Fractyl, Terns
- Amylin / triple agonists (various) — Sciwind, others
- TERN-800 series — Terns Pharmaceuticals
- RJVA-002 — Fractyl Health
- VRB-103 — Verdiva Bio
- VRB-104 — Verdiva Bio
- Oral amylin RA — Sciwind Biosciences